vimarsana.com
Home
Live Updates
Lyra Therapeutics Announces Completion of Enrollment in the : vimarsana.com
Lyra Therapeutics Announces Completion of Enrollment in the
-- Topline Results Expected in Q4 2023 -- -- LYR-220 is Lyra’s Second Product Candidate, Following LYR-210 in Surgically-Naïve CRS patients -- WATERTOWN,...
Related Keywords
United States ,
Russia ,
Ukraine ,
Richard Nieman ,
Ellen Cavaleri ,
Int Forum Allergy Rhinol ,
Company Or Lyra ,
Lyra Therapeutics Inc ,
Nasdaq ,
Results Expected ,
Second Product Candidate ,
Chief Medical Officer ,
Sino Nasal Outcome Test ,
Private Securities Litigation Reform Act ,
Quarterly Report ,
Investor Relations ,
Forum Allergy ,
Nasdaq Lyra ,
Lyra Therapeutics ,
vimarsana.com © 2020. All Rights Reserved.